All In Biotech

NDA 021994 · Sandoz

Travatan Z

Travoprost · Ophthalmic · Prostaglandin Analog

Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Sep 21, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

137

36 Phase 3, 4 recruiting

FAERS reports

8,671

3,182 serious, 333 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2025.

TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. TRAVATAN Z is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (1)

Mechanism: Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 31, 2010 Supplement 1 · Efficacy LabelLetter
  • Sep 21, 2006 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
1 products under this application
  • TRAVATAN Z · TRAVOPROST 0.004% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2

Clinical trials

Interventional ClinicalTrials.gov studies with "Travoprost" as an intervention, any sponsor and status, largest first.

All 137 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,951
  • drug ineffective545
  • ocular hyperaemia503
  • eye irritation499
  • eye pain352
  • intraocular pressure increased299
  • hypersensitivity269
  • fatigue268
  • glaucoma260
  • headache237
  • dizziness236
  • vision blurred236

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200547
200632
200735
200837
200955
201068
201185
2012114
2013113
2014164
2015361
2016633
2017821
2018792
2019743
20202,608
2021483
2022355
2023291
2024253
2025325
2026240

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Travatan Z (Travoprost)

2024 spending

$10.6M

Beneficiaries

5,919

21,212 claims

Per beneficiary

$1,790

$91.83 per unit

View as table
YearSpending
2020$2,141,146
2021$19,268,531
2022$14,924,685
2023$12,901,633
2024$10,595,167

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 206 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.